Furmonertinib plus local therapy for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a targeted pill (furmonertinib) combined with local treatments like radiation or heat/cold to destroy the tumor can help people with early-stage lung cancer that has specific genetic changes (EGFR mutations). It aims to control the cancer without surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage non-small cell lung cancer (T1-3 N0) that hasn't spread to lymph nodes or elsewhere.
- Your cancer has certain EGFR gene changes (like exon 19 deletion or L858R) confirmed by a genetic test.
- You are 18 years or older.
- You are generally able to care for yourself (ECOG score 0-2).
- Your doctors have decided that surgery is not an option or you have chosen not to have surgery.
- Your lung tumors are suitable for either ablation (using heat or cold to destroy them) or radiation therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.